Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00112658 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 / Phase 3 | 342 | UNICANCEROTHER | 1 | Mar 8, 2021 | clinicaltrials |
| NCT00066677 |
| Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer |
| terminated |
| Phase 2 |
| 32 |
| Fox Chase Cancer CenterOTHER |
| 1 |
| Mar 5, 2021 |
| clinicaltrials |
| NCT00376948 | Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01838317 | A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas | completed | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT03374293 | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 21 | Shixiu WuOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02921737 | TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) | terminated | Phase 2 | 7 | University of FloridaOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03415802 | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | completed | Phase 2 | 32 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04723030 | The Transformation of Locally Advanced Pancreatic Cancer. | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03986294 | Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer(NAPAN) | unknown | Phase 2 | 122 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | terminated | Phase 2 | 40 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00003531 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT01652976 | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma(FOLFOX-D) | completed | Phase 2 | 44 | University of FloridaOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT00560963 | Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | completed | Phase 1 / Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT04183478 | The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 600 | RenJi HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02896803 | Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer(PanFLOX) | unknown | Phase 2 | 37 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT01397019 | Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours | completed | Phase 2 | 56 | Per PfeifferOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02459652 | Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 57 | Japan Adjuvant Study Group of Pancreatic CancerOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04581876 | The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT04571489 | A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 60 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | terminated | Phase 2 | 28 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02289898 | Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma(YOSEMITE) | completed | Phase 2 | 207 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 6 | Sep 28, 2020 | clinicaltrials |
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | terminated | Phase 2 | 21 | Andrew KoOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02717091 | Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | unknown | Phase 2 | 50 | Nagoya UniversityOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02172976 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | completed | Phase 2 / Phase 3 | 40 | Krankenhaus NordwestOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00267020 | Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 130 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT00094445 | Trial of Curcumin in Advanced Pancreatic Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT01560949 | Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04498689 | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | unknown | Phase 2 | 117 | Fudan UniversityOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03469258 | Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00882765 | Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01222689 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03681951 | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | terminated | Phase 2 | 8 | GlaxoSmithKlineINDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02402062 | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | completed | Phase 2 | 17 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01839487 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | completed | Phase 2 | 279 | Halozyme TherapeuticsINDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 9, 2021source: clinicaltrials